If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Zepbound ® (tirzepatide) injection
2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How do you treat a Zepbound® (tirzepatide) overdose?
In the event of an overdosage, contact Poison Help Line or a medical toxicologist for overdosage management recommendations.
See important safety information, including boxed warning, in the attached prescribing information.
Approved Dosages
The recommended starting dose of tirzepatide is 2.5 mg injected subcutaneously once weekly. The 2.5 mg dosage is for treatment initiation and is not intended for chronic weight management.1
The recommended maintenance dosages of tirzepatide in adults are 5, 10, or 15 mg injected subcutaneously once weekly.1
The maximum dosage of tirzepatide is 15 mg injected subcutaneously once weekly.1
Overdose
In the event of an overdosage, contact the Poison Help Line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations.1
Appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms.1
A period of observation and treatment for these symptoms may be necessary, considering the half-life of tirzepatide is approximately 5 days.1
Enclosed Prescribing Information
Reference
1Zepbound [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
Date of Last Review: November 02, 2024